Evaluation of AP-002 in Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to define an effective and safe dose of AP-002 in advanced or
recurrent solid tumors for which there are no standard therapies to use in subsequent studies
in advanced or recurrent breast, non-small cell lung cancer (NSCLC) or prostate cancers.